All patients with major adverse cardiac events, includ--ing death, MI, target lesion revascularization, and stent thrombosis in the first 6 months after the initial stent implant were excluded from the analysis. Since the vast majority of adverse events with bare-metal stents oc--cur in the first 6 months, this study design biased the results in favor of bare-metal stents. Indeed, patients with bare-metal stents who have no stent thrombosis, MI or clinical restenosis events at 6 months had a favor--able long-term clinical outcome. Conversely, the rate of major adverse cardiac events with bare-metal stents in the first 6 to 9 months is significantly higher than with drug-eluting stents, [4] [5] [6] It is this substantial reduction of major adverse cardiac events in the first 6 to 9 months that provides the rationale for drug-eluting stent use. A trial design that eliminates all of the adverse events that occur in the first 6 months after bare-metal stent implantation creates a biased result in an effort to show that bare-metal stents are as good as or better than drug-eluting stents.
One study 3 that focused on total mortality analyzed 17 randomized clinical trials of bare-metal stents ver--sus drug-eluting stents. This study found a higher to--tal mortality rate in the sirolimus subgroup at a 2-year follow-up. Although the difference in total mortality was significant (P=.03), it was due to more noncardiac deaths in the sirolimus group (mainly from the RAVEL subgroup), primarily from concomitant comorbidi--ties, including lung disease, cancer, and strokes. There were no differences between the drug-eluting stent and bare-metal stent groups in cardiac mortality, but there were no details provided as to the number of patients analyzed in each group. Others have suggested that these noncardiac deaths were somehow related to the drug-eluting stent implant. However, any relationship between 180 µg of sirolimus, eluted locally into a coro--nary artery over 60 to 90 days with fatal strokes, lung cancers, and chronic obstructive pulmonary disease, is difficult to explain.
Another study that has been given worldwide atten--tion is a meta-analysis, presented at the World Congress of Cardiology in 2006, of data from selected CYPHER and TAXUS trials up to 2 years from implantation. 2 The main conclusion from the analysis was that death and MI were higher for drug-eluting stents compared with bare-metal stents, and that this finding was sig--nificant for pooled CYPHER versus bare-metal stents studies, at a 2-year period. 2 There are several questions about this analysis. First, it is unclear if all death or cardiac death was analyzed in TAXUS data set. The data sources used in the analysis were not well defined, and the sample sizes at different time points were not shown. The analysis appears to have used a summary of data from the literature instead of patient-level data.
Two independent academic cardiology research programs have critically analyzed the more complete, patient level data from more than 1600 patients from the same four randomized clinical trials of bare-metal stents versus CYPHER (SIRIUS, RAVEL, C-SIRIUS and E-SIRIUS trials), and follow-up data was obtained up to 4 years. 7, 8 These independent investigators were unable to confirm the risks of drug-eluting stents that were presented in the meta-analysis. In the four tri--als included in the meta-analysis, the total (definite and probable) stent thrombosis rates, using the ARC (Academic Research Consortium) definition, with 0 to 4 years of follow-up, were 1.8% (15/843 patients) in the bare-metal stent group and 1.5% (13/848 patients) in the CYPHER group (P=NS). At 4-years follow-up there was no significant differences in stent thrombosis, cardiac or noncardiac deaths, or MI. 7, 8 When a more complete set of data from 5007 patients from all 14 randomized clinical trials of bare-metal stents versus CYPHER were analyzed, none of the risks with drugeluting stents could be identified that were presented in the BASKET Late report or the meta-analyses. 7, 8 The total stent thrombosis rate with a mean follow-up of about 24 months was 1.62% for bare-metal stents vs. 1.47% with CYPHER (P=NS). There were no statisti--cally significant differences in death or MI after 1, 2, or 4 years of follow-up. Surprisingly, the researchers who reported concerns with drug-coated stents in 2006, 2 found in 2007 that there was actually no difference in death rates, and that "drug-coated stents were safe af--ter all." This turnabout demonstrates how researchers can draw seemingly conflicting conclusions, based on small differences in the design or interpretation of stud--ies, creating confusion for doctors and patients alike. Another study 9 found that drug-coated stents were as safe as or safer than bare-metal stents when doctors used them ' off-label.' Interestingly, reported studies with angiographic confirmation on all late thrombosis events (>30 days) identified a very low incidence (only 0.16%-0.27%).
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Pathologic studies of late stent thrombosis cases also suffer from potential sampling bias. These cases, howev--er, do show endothelial cell disruption, some inflamma--tion, and delayed healing.
14 The more important ques--tion is whether these findings are relevant to the vast majority of patients who do not have restenosis or stent thrombosis 3 to 4 years after drug-eluting stent implan--tation, and 2 to 3 years after stopping clopidogrel.
Causes of stent thrombosis
Both early and late stent thrombosis are complex events with a multifactorial etiology. Lesion complexity, over--lapping stents, long stent lengths, bifurcation lesions, stenting in acute MI, stent underdeployment, diabe--tes, renal failure, and premature discontinuation of antiplatelet agents are significant risk factors for stent thrombosis with both bare-metal stents and drug-elut--ing stents. [15] [16] [17] [18] [19] It is important to recognize that many of the major risk factors for stent thrombosis have been substantially amplified in the drug-eluting stents era by the use of these stents in complex lesions. Many of these uses are in clinical settings and lesion subsets that extend be--yond approved indications, but still may be clinically reasonable, with overall risks that are as low as or lower than medical therapy, bare-metal stent use or bypass surgery. Nonetheless, this very aggressive use of drugeluting stents, which is made possible by the very effec--tive reduction of restenosis, may lead to higher risks of stent thrombosis.
Patient and physician noncompliance with guide--line-based prescription of dual antiplatelet therapy also plays a significant role in drug-eluting stent thrombo--sis. A registry from Rotterdam 19 showed that among patients who had a late stent thrombosis with drugeluting stents (occurring after 30 days), only 26% of patients were still taking dual antiplatelet therapy, 51% were taking single antiplatelet therapy, and 23% were taking no antiplatelet medications. Importantly, as with bare-metal stents, premature discontinuation of dual antiplatelet therapy is the strongest risk factor in drugeluting stent thrombosis.
The causes of very late stent thrombosis (i.e., after 1 year) are less certain. It is possible that the vessels still are not healed. Endothelialization of these devices after deployment in the coronary artery is delayed compared with bare-metal stents. 20 Delayed hypersensitivity to the polymer/drug coating with intense local inflammatory cell infiltration and aneurysmal dilatation of the vessel wall has also been described, 21 as has adverse late vessel wall remodeling associated with the development of in--complete drug-eluting stent apposition. 22 In preclinical animal models, this delay in re-endothelialization, and the presence of inflammation appears more pronounced with the paclitaxel-eluting TAXUS stent than with si--rolimus-eluting CYPHER stent. However, since stent thrombosis rates with TAXUS and CYPHER appear similar, these observations may not be relevant to clini--cal outcomes, particularly with longer duration thieno--pyridine prophylaxis. Whether vascular inflammatory reactions observed in a selected number of individuals are related to the drug delivery polymer is uncertain. 14 At present, patients who receive a drug-eluting stents implant are instructed to take clopidogrel for at least 6 months (as compared to 2 to 4 weeks after baremetal stent implantation), and often indefinitely. By 6 to 12 months after a drug-eluting stents implant, most patients should have an intact endothelial cell layer.
Misconceptions about revascularization

Early thrombosis (within 30 days)
The concern about the use of drug-eluting stents is based on false assumptions related to the risks of stent thrombosis. The premise that bare-metal stents do not thrombose, or have a very low incidence of stent throm--bosis, is misguided. The critical issue is the total inci--dence of stent thrombosis over the life of the implant. Even more relevant is the incidence of all major adverse cardiac events related to the target lesion over the life of the patient, beginning from the time of the index pro--cedure onward.
Bare-metal stents have a substantial risk of both acute, subacute and late stent thrombosis. 15, 16, [23] [24] [25] [26] [27] [28] In one study involving bare-metal stents in a single lesion using a single stent, the 30-day stent thrombosis risk for these simple lesions was 2%. 23 In another study look--ing at bare-metal stents versus heparin-coated stents, the 30-day stent thrombosis rate with bare-metal stents was at least 2.5%. 24 Other trials with bare-metal stents also suggest a 1.5% to 3% incidence of stent thrombosis, in real-world stenting, and with a rare follow-up past 1 year. 13, 14, [18] [19] [20] [21] [22] [23] Thus, even with relatively short-term fol--low-up, in both simple and more complex lesions, the rate of bare-metal stent thrombosis is higher than most physicians perceive.
In the ARTS 1 trial comparing bare-metal stents versus coronary artery bypass grafting (CABG) for multivessel disease (2.8 stents and 47.6 mm mean stent length per patient), the 30-day stent thrombosis rate with bare-metal stents was 2.8%. 25 In the ARTS 2 Trial, using an average of 3.7 CYPHER implants (mean stent length, 72.5 mm) per patient, the 30-day stent thrombosis rate with CYPHER was 0.9%. 29 This was significantly lower than the bare-metal stents early thrombosis risk (P<.009), despite a much higher-risk case mix in the patients treated with CYPHER stent in ARTS 2.
Late thrombosis (after 30 days)
The premise that bare-metal stents do not thrombose after 30 days is also incorrect. Less attention has been directed to this issue in the era of bare-metal stents. However, in the two large published registries 26, 27 evalu--ating late bare-metal stents thrombosis (30 to 240-270 days), the late bare-metal stents thrombosis rates were 0.75% and 0.64%. When added to the early stent throm--bosis rates in these studies the overall stent thrombosis with bare-metal stents with less than 1 year follow up was at least 2%. In one study looking at treatment of bare-metal stent thrombosis, approximately one-third of bare-metal stent thrombosis occurred late, with some cases observed up to 600 days after bare-metal stent im--plantation. 28 In the pooled analysis of CYPHER versus bare-met--al stents from 12 randomized clinical trials, the 30-day to 1-year rate of stent thrombosis was 0.62% for the bare-metal stents and 0.29% for CYPHER. 7, 8 A recent meta-analysis looking at both CYPHER and TAXUS showed no difference in late stent thrombosis out to 1 year vs. bare-metal stents. 30 In the DEScover Registry, which enrolled 6906 real-world patients, the 1-year stent thrombosis rates were 0.8% for bare-metal stents, 0.8% for TAXUS, and 0.5% for CYPHER, despite sub--stantially higher risk lesions treated in the drug-eluting stent subgroups. 31 Finally, the one-year stent throm--bosis rate with CYPHER in 15 157 patients in the e-CYPHER registry was very low (0.88%) in complex real-world cases. 13 Thus, bare-metal stents definitely do thrombose af--ter 30 days, due to incomplete endothelial cell regrowth, stent under-expansion, and critical restenosis with su--perimposed thrombus. Although the mechanism(s) of late stent thrombosis with bare-metal stents may differ from drug-eluting stents, the overall incidence appears to be at least 1%, over a 30-day to 2-year follow-up, and not clearly lower than with drug-eluting stents.
Restenosis is not totally benign
Restenosis of bare-metal stents is neither rare, nor be--nign. The concept that we are trading a low incidence and low-risk restenosis event for a morbid late thrombo--sis event, thereby justifying the use of bare-metal stents rather than drug-eluting stents, ignores a number of very important points. First, restenosis of bare-metal stents is not benign. In one large study from the Cleveland Clinic, 36% of bare-metal stent restenosis cases pre--sented with acute coronary syndromes requiring urgent hospitalization. 32 Approximately 25% of these patients presented with either non-q wave or an ST-elevation MI. Assuming a 30% bare-metal stent restenosis rate; there is a 5% to 7% risk of acute MI risk related directly to severe restenosis of a bare-metal stent.
There is a remarkable (approximately 70%-80%) re--duction of major adverse cardiac events (predominantly repeat revascularization) with drug-eluting stents ver--sus bare-metal stents. Both the TAXUS and CYPHER products substantially reduce the need for repeat target lesion reintervention, with a reduction of the costs, risks and pain and suffering related to repeat interventions for restenosis. [4] [5] [6] Forty to fifty percent of bare-metal stent restenosis presents with vessel occlusion or diffuse proliferative in-stent restenosis. These patients often do poorly after repeat intervention with drug-elut--ing stents, bare-metal stents, percutaneous translumi--nal coronary angioplasty (PTCA), brachytherapy, or CABG. Restenosis of bare-metal stents is not benign, and has significant associated major adverse cardiac events, financial and emotional costs, and mortality.
Bypass surgery is not totally benign and grafts do close
If drug-eluting stents are imperfect, perhaps coronary bypass surgery offers a safer and more durable revascu--larization result. This may drive more referrals to bypass surgery, since bypass grafts are often considered a gold standard, when it comes to predictable coronary revas--cularization. There is an assumption that bypass graft patency is grossly superior to bare-metal stents, and even drug-eluting stents, but this is not true either. Two recent studies in the New England Journal of Medicine 33 and Circulation, 34 reported angiographic follow-up data at 12 months to assess the patency rates of radial artery grafts, internal mammary artery grafts (IM), and saphe--nous vein grafts (SVGs). In these two studies the oneyear (angiographic) patency rates of SVGs were 85% and 59%, respectively. That is, 15% to 41% of SVGs were completely occluded at 12 months. The arterial conduits were better. However, 14.2% of the radial ar--tery grafts and 6% to 7% of the IM grafts were com--pletely occluded or nonfunctional at 12 months. These results are also consistent with the PREVENT IV study with 3000 patients, which demonstrated a 40% SVG failure rate at 1-year angiographic follow-up. 35 In addition, other studies have described a 2% to 3% major stroke rate and a 10% to 20% incidence of perma--nent cognitive impairment after CABG. 36 These results suggest that, like PTCA, bare-metal stents, and drugeluting stents, CABG surgery is not perfect either.
Patient Selection/Challenges
Proper patient selection should involve an assessment of the balance between restenosis risk and thrombosis risk (and the consequences of restenosis and thrombo--sis). Many factors, such as diabetes, long lesions, small vessels, chronic kidney disease and lesions in SVGs, have been identified that portend a higher risk of re--stenosis and may shift the benefit:risk ratio in favor of drug-eluting stents. These subgroups may also have a higher risk of very late thrombosis. It is important for the clinician to consider the risk:benefit ratio for each individual patient.
Consideration must be given to the patient' s abil--ity to comply with long-term dual antiplatelet therapy. Social, medical, and financial barriers to proper adher--ence must be considered before a drug-eluting stent is selected for implantation, and in particular, the likeli--hood of future bleeding risk or need for surgical/in--vasive procedures should be carefully assessed. Drugeluting stent implantation should be avoided if there is any doubt that the patient can comply with prolonged dual antiplatelet therapy.
Patients with previously implanted drug-eluting stents who are currently taking dual antiplatelet ther--apy present a significant management challenge to the cardiologist or primary care provider when a situation arises that requires cessation or interruption of antiplatelet therapy (for example, when elective or urgent surgery is required). There are no existing studies that examine alternative management strategies. Each prac--titioner must therefore rely on personal knowledge of the individual patient, the specific reason(s) for antiplatelet therapy discontinuation and other relevant fac--tors in making the recommendation for how to manage the situation. Unlike available recommendations for al--ternative anti-coagulant bridging strategies when war--farin therapy must be temporarily discontinued, there are no existing data or recommendations for the prac--titioner to minimize the risk of stent thrombosis when anti-platelet therapy must be stopped. Discussion of the risks and benefits with the surgeon or other practi--tioner should be undertaken to determine if the proce--dure could be performed with reasonable safety with--out discontinuation of antiplatelet agents. In the patient considered at high risk for stent thrombosis involving a large area of myocardium, short-acting intravenous glycoprotein IIb/IIIa inhibitors have been empirically suggested prior to and after surgery for platelet inhibi--tion during the period when the patient is unprotected between clopidogrel discontinuation to re-initiation. However, the safety and efficacy of this practice has not been formally studied. Similarly, there are no data to support bridging with low molecular weight heparin.
Conclusions
The purpose of this review of stent safety and indica--tion is to provide some counterpoint to some of the attention surrounding issues of late drug-eluting stent thrombosis. The important take-home message is that the risks of drug-eluting stent thrombosis versus baremetal stent thrombosis may have been overstated by some studies. Late stent thrombosis does occur with both bare-metal stents and drug-eluting stents, and may or may not be modestly higher with drug-elut--ing stents. The time course of very late drug-eluting stents thrombosis, suggests that persistent plaque rup--tures and disease progression in the target vessel may cause some, or many of these events. The implantation of bare-metal stents as an alternative to drug-eluting stents will be associated with incremental morbidity, particularly in higher risk lesion and patient subsets. Yet, bare-metal stents can be recommended for one particular subgroup of patients who cannot take pro--longed dual antiplatelet therapy for various reasons such as anticipated poor compliance, inability to afford medications, need for noncardiac surgery, and increased risk for bleeding complications.
There is still much to be learned about the biol--ogy of drug-eluting stents. However, there is no ques--tion that this technology provides tremendous benefit to the vast majority of patients compared with prior revascularization strategies. Clinicians and scientists should work on improving antiplatelet regimens and developing newer generation of biocompatible drugeluting stents, which have biodegradable polymers or are polymer-free to minimize the risks of stent throm--bosis.
